サマリー

ヒト凝固第VIII因子は、血液凝固に不可欠なタンパク質で、抗好血液性因子（AHF）とも呼ばれる。ヒトでは、第VIII因子はF8遺伝子にコードされており、この遺伝子に欠損があると血友病Aとなります。血友病患者には、献血した血漿から濃縮したヒト凝固第VIII因子（AafactまたはAlphanate、モノクレートP®）、あるいは遺伝子組み換えヒト凝固第VIII因子が、止血を回復するために投与されることがあります。
市場分析および洞察。ヒト凝固第VIII因子の世界市場
COVID-19の大流行により、世界のヒト凝固第VIII因子市場規模は2022年に1億9000万米ドルと推定され、レビュー期間中にCAGR6.3％で2028年までに1億5770万米ドルに再調整されると予測されています。この健康危機による経済変化を十分に考慮し、2021年にヒト凝固第VIII因子世界市場の％を占めた組換え第VIII因子は、2028年までに100万米ドルの価値を持ち、COVID-19後の期間に改訂された％のCAGRで成長すると予測されています。一方、血友病Aセグメントは、この予測期間を通して％CAGRに変更されています。
世界のヒト凝固第VIII因子主要プレイヤーは、バクスター、バイエル、CSL、ファイザー、バイオジェンなどです。世界の上位5社で約80％のシェアを占めています。北米が最大の市場であり、約60％のシェア、次いで欧州が約30％のシェアとなっています。製品別では、遺伝子組換え第VIII因子が最大のセグメントで、約65％のシェアを持っています。また、用途別では、血友病Aが最も多く、次いで自然発症/外傷、外科用などとなっています。
世界のヒト凝固第VIII因子製剤の範囲とセグメント
ヒト凝固第VIII因子市場は、タイプ別および用途別に分類されます。世界のヒト凝固因子VIII市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができます。セグメント別分析では、2017年から2028年までのタイプ別およびアプリケーション別の売上、収益、予測に焦点を当てています。
タイプ別セグメント
遺伝子組換え第VIII因子
血漿由来第VIII因子
用途別セグメント
血友病A
自然発症・外傷
外科手術
その他
会社別
シャイアー（バクスター）
バイエル
CSL
ファイザー
グリフォルス
バイオジェン
オクタファーマ
ノボノルディスク
グリーンクロス
ケドリオン
BPL
花蘭バイオ
RAAS
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋地域
中国
日本
韓国
インド
オーストラリア
台湾
インドネシア
タイ
マレーシア
フィリピン
ベトナム
中南米
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
U.A.E.

ページTOPに戻る

目次

1 Study Coverage
1.1 Human Coagulation Factor VIII Product Introduction
1.2 Market by Type
1.2.1 Global Human Coagulation Factor VIII Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Recombinant Factor VIII
1.2.3 Plasma-derived Factor VIII
1.3 Market by Application
1.3.1 Global Human Coagulation Factor VIII Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hemophilia A
1.3.3 Spontanous / Trauma
1.3.4 Surgical
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Human Coagulation Factor VIII Sales Estimates and Forecasts 2017-2028
2.2 Global Human Coagulation Factor VIII Revenue Estimates and Forecasts 2017-2028
2.3 Global Human Coagulation Factor VIII Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Human Coagulation Factor VIII Sales by Region
2.4.1 Global Human Coagulation Factor VIII Sales by Region (2017-2022)
2.4.2 Global Sales Human Coagulation Factor VIII by Region (2023-2028)
2.5 Global Human Coagulation Factor VIII Revenue by Region
2.5.1 Global Human Coagulation Factor VIII Revenue by Region (2017-2022)
2.5.2 Global Human Coagulation Factor VIII Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Human Coagulation Factor VIII Sales by Manufacturers
3.1.1 Global Top Human Coagulation Factor VIII Manufacturers by Sales (2017-2022)
3.1.2 Global Human Coagulation Factor VIII Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Coagulation Factor VIII in 2021
3.2 Global Human Coagulation Factor VIII Revenue by Manufacturers
3.2.1 Global Human Coagulation Factor VIII Revenue by Manufacturers (2017-2022)
3.2.2 Global Human Coagulation Factor VIII Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Human Coagulation Factor VIII Revenue in 2021
3.3 Global Human Coagulation Factor VIII Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Human Coagulation Factor VIII Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Human Coagulation Factor VIII Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Coagulation Factor VIII Sales by Type
4.1.1 Global Human Coagulation Factor VIII Historical Sales by Type (2017-2022)
4.1.2 Global Human Coagulation Factor VIII Forecasted Sales by Type (2023-2028)
4.1.3 Global Human Coagulation Factor VIII Sales Market Share by Type (2017-2028)
4.2 Global Human Coagulation Factor VIII Revenue by Type
4.2.1 Global Human Coagulation Factor VIII Historical Revenue by Type (2017-2022)
4.2.2 Global Human Coagulation Factor VIII Forecasted Revenue by Type (2023-2028)
4.2.3 Global Human Coagulation Factor VIII Revenue Market Share by Type (2017-2028)
4.3 Global Human Coagulation Factor VIII Price by Type
4.3.1 Global Human Coagulation Factor VIII Price by Type (2017-2022)
4.3.2 Global Human Coagulation Factor VIII Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Human Coagulation Factor VIII Sales by Application
5.1.1 Global Human Coagulation Factor VIII Historical Sales by Application (2017-2022)
5.1.2 Global Human Coagulation Factor VIII Forecasted Sales by Application (2023-2028)
5.1.3 Global Human Coagulation Factor VIII Sales Market Share by Application (2017-2028)
5.2 Global Human Coagulation Factor VIII Revenue by Application
5.2.1 Global Human Coagulation Factor VIII Historical Revenue by Application (2017-2022)
5.2.2 Global Human Coagulation Factor VIII Forecasted Revenue by Application (2023-2028)
5.2.3 Global Human Coagulation Factor VIII Revenue Market Share by Application (2017-2028)
5.3 Global Human Coagulation Factor VIII Price by Application
5.3.1 Global Human Coagulation Factor VIII Price by Application (2017-2022)
5.3.2 Global Human Coagulation Factor VIII Price Forecast by Application (2023-2028)
6 North America
6.1 North America Human Coagulation Factor VIII Market Size by Type
6.1.1 North America Human Coagulation Factor VIII Sales by Type (2017-2028)
6.1.2 North America Human Coagulation Factor VIII Revenue by Type (2017-2028)
6.2 North America Human Coagulation Factor VIII Market Size by Application
6.2.1 North America Human Coagulation Factor VIII Sales by Application (2017-2028)
6.2.2 North America Human Coagulation Factor VIII Revenue by Application (2017-2028)
6.3 North America Human Coagulation Factor VIII Market Size by Country
6.3.1 North America Human Coagulation Factor VIII Sales by Country (2017-2028)
6.3.2 North America Human Coagulation Factor VIII Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Human Coagulation Factor VIII Market Size by Type
7.1.1 Europe Human Coagulation Factor VIII Sales by Type (2017-2028)
7.1.2 Europe Human Coagulation Factor VIII Revenue by Type (2017-2028)
7.2 Europe Human Coagulation Factor VIII Market Size by Application
7.2.1 Europe Human Coagulation Factor VIII Sales by Application (2017-2028)
7.2.2 Europe Human Coagulation Factor VIII Revenue by Application (2017-2028)
7.3 Europe Human Coagulation Factor VIII Market Size by Country
7.3.1 Europe Human Coagulation Factor VIII Sales by Country (2017-2028)
7.3.2 Europe Human Coagulation Factor VIII Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Coagulation Factor VIII Market Size by Type
8.1.1 Asia Pacific Human Coagulation Factor VIII Sales by Type (2017-2028)
8.1.2 Asia Pacific Human Coagulation Factor VIII Revenue by Type (2017-2028)
8.2 Asia Pacific Human Coagulation Factor VIII Market Size by Application
8.2.1 Asia Pacific Human Coagulation Factor VIII Sales by Application (2017-2028)
8.2.2 Asia Pacific Human Coagulation Factor VIII Revenue by Application (2017-2028)
8.3 Asia Pacific Human Coagulation Factor VIII Market Size by Region
8.3.1 Asia Pacific Human Coagulation Factor VIII Sales by Region (2017-2028)
8.3.2 Asia Pacific Human Coagulation Factor VIII Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Human Coagulation Factor VIII Market Size by Type
9.1.1 Latin America Human Coagulation Factor VIII Sales by Type (2017-2028)
9.1.2 Latin America Human Coagulation Factor VIII Revenue by Type (2017-2028)
9.2 Latin America Human Coagulation Factor VIII Market Size by Application
9.2.1 Latin America Human Coagulation Factor VIII Sales by Application (2017-2028)
9.2.2 Latin America Human Coagulation Factor VIII Revenue by Application (2017-2028)
9.3 Latin America Human Coagulation Factor VIII Market Size by Country
9.3.1 Latin America Human Coagulation Factor VIII Sales by Country (2017-2028)
9.3.2 Latin America Human Coagulation Factor VIII Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Coagulation Factor VIII Market Size by Type
10.1.1 Middle East and Africa Human Coagulation Factor VIII Sales by Type (2017-2028)
10.1.2 Middle East and Africa Human Coagulation Factor VIII Revenue by Type (2017-2028)
10.2 Middle East and Africa Human Coagulation Factor VIII Market Size by Application
10.2.1 Middle East and Africa Human Coagulation Factor VIII Sales by Application (2017-2028)
10.2.2 Middle East and Africa Human Coagulation Factor VIII Revenue by Application (2017-2028)
10.3 Middle East and Africa Human Coagulation Factor VIII Market Size by Country
10.3.1 Middle East and Africa Human Coagulation Factor VIII Sales by Country (2017-2028)
10.3.2 Middle East and Africa Human Coagulation Factor VIII Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Shire (Baxter)
11.1.1 Shire (Baxter) Corporation Information
11.1.2 Shire (Baxter) Overview
11.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Shire (Baxter) Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Shire (Baxter) Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Overview
11.2.3 Bayer Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bayer Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Recent Developments
11.3 CSL
11.3.1 CSL Corporation Information
11.3.2 CSL Overview
11.3.3 CSL Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 CSL Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CSL Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Pfizer Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Grifols
11.5.1 Grifols Corporation Information
11.5.2 Grifols Overview
11.5.3 Grifols Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Grifols Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Grifols Recent Developments
11.6 Biogen
11.6.1 Biogen Corporation Information
11.6.2 Biogen Overview
11.6.3 Biogen Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Biogen Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Biogen Recent Developments
11.7 Octapharma
11.7.1 Octapharma Corporation Information
11.7.2 Octapharma Overview
11.7.3 Octapharma Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Octapharma Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Octapharma Recent Developments
11.8 NovoNordisk
11.8.1 NovoNordisk Corporation Information
11.8.2 NovoNordisk Overview
11.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 NovoNordisk Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 NovoNordisk Recent Developments
11.9 Greencross
11.9.1 Greencross Corporation Information
11.9.2 Greencross Overview
11.9.3 Greencross Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Greencross Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Greencross Recent Developments
11.10 Kedrion
11.10.1 Kedrion Corporation Information
11.10.2 Kedrion Overview
11.10.3 Kedrion Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Kedrion Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Kedrion Recent Developments
11.11 BPL
11.11.1 BPL Corporation Information
11.11.2 BPL Overview
11.11.3 BPL Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 BPL Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 BPL Recent Developments
11.12 Hualan Bio
11.12.1 Hualan Bio Corporation Information
11.12.2 Hualan Bio Overview
11.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Hualan Bio Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Hualan Bio Recent Developments
11.13 RAAS
11.13.1 RAAS Corporation Information
11.13.2 RAAS Overview
11.13.3 RAAS Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 RAAS Human Coagulation Factor VIII Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 RAAS Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Coagulation Factor VIII Industry Chain Analysis
12.2 Human Coagulation Factor VIII Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Coagulation Factor VIII Production Mode & Process
12.4 Human Coagulation Factor VIII Sales and Marketing
12.4.1 Human Coagulation Factor VIII Sales Channels
12.4.2 Human Coagulation Factor VIII Distributors
12.5 Human Coagulation Factor VIII Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Human Coagulation Factor VIII Industry Trends
13.2 Human Coagulation Factor VIII Market Drivers
13.3 Human Coagulation Factor VIII Market Challenges
13.4 Human Coagulation Factor VIII Market Restraints
14 Key Findings in The Global Human Coagulation Factor VIII Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer